A long-term solution to slow disease
progression, helping patients maintain
vision and quality of life.
Neurotech spent years developing the science, technology, team and manufacturing behind NT-501. As a result of a unique partnership and clear direction, we are focused on bringing a long-term treatment to Macular Telangiectasia (MacTel) patients. Our team is focused on bringing to market this treatment designed to slow the progression of MacTel and the vision impairments it causes in patients who don’t have another treatment option. Our goal is to help these patients sustain their quality of life.
Macular Telangiectasia (MacTel)
MacTel is a bilateral retinal disease that leads to a gradual loss of central vision. The disease causes photoreceptors to be lost in a well-defined area (Ellipsoid Zone) of the retina. As the disease progresses, patients experience blurring, distorted vision, trouble reading, and loss of central vision. Our delivery system releases Ciliary Neurotrophic Factor (CNTF), a protein shown to protect against the progressive loss of photoreceptors.
We manufacture an implantable device containing genetically-modified cells that release protein-based therapeutics. This is a versatile drug delivery platform designed for long-term, sustained use.
We have clinical evidence showing effective treatment durability for several years.